Literature DB >> 8941670

Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA.

K Asadullah1, W D Döcke, A Haeussler, W Sterry, H D Volk.   

Abstract

Cytokines are believed to play an important role in the pathogenesis of cutaneous T cell lymphoma. Data regarding the local cytokine pattern in mycosis fungoides (MF) are partly conflicting. Recent studies have suggested a shift from type 1 to type 2 cytokine pattern because IL-4 and IL-5 mRNA have been more frequently detected in lesions of advanced stages. Another study has described a type 1 cytokine pattern in MF lesions. None of the previous studies of cytokine mRNA expression in MF, however, used quantitative methods, and therefore only the presence of a cytokine, but not the level of expression, could be determined. To gain better insight into the development of cytokine pattern during tumor progression we used semiquantitative reverse transcriptase-polymerase chain reaction to analyze cytokine mRNA expression in MF skin lesions at different stages. Biopsies from patients with patch (n = 11), plaque (n = 6), and tumor (n = 3) stage MF were compared with biopsies from patients with pleomorphic T cell lymphoma (n = 5), psoriasis (n = 7), atopic dermatitis (n = 5), and nonlesional skin (n = 8). MF progression was associated with significantly higher IL-10 and lower interferon-gamma mRNA expression. Moreover, the stage-dependent increase in IL-10 mRNA expression was also found in paired samples from individual patients. Unlike in pleomorphic T cell lymphoma, however, typical T helper 2 cells did not seem to be the source of increasing IL-10 in advanced MF, because stage-independent IL-4 mRNA was rarely detected, suggesting contribution of nonlymphoid cells to local IL-10 production. The overexpression of IL-10 in MF may be of importance for tumor progression, because this immunosuppressive cytokine might be involved in downregulation of immunologic tumor surveillance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8941670     DOI: 10.1111/1523-1747.ep12330869

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  20 in total

1.  Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model.

Authors:  L Chen; O Martinez; L Overbergh; C Mathieu; B S Prabhakar; L S Chan
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

2.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

Review 3.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

4.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.

Authors:  K Asadullah; W Sterry; K Stephanek; D Jasulaitis; M Leupold; H Audring; H D Volk; W D Döcke
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

5.  The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

Authors:  Michael J Kelly-Sell; Youn H Kim; Suzanne Straus; Bernice Benoit; Cameron Harrison; Katherine Sutherland; Randall Armstrong; Wen-Kai Weng; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

6.  IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

Authors:  Hanako Ohmatsu; Daniel Humme; Juana Gonzalez; Nicholas Gulati; Markus Möbs; Wolfram Sterry; James G Krueger
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

7.  Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.

Authors:  Xuesong Wu; Brian C Schulte; Youwen Zhou; Dipica Haribhai; Alexander C Mackinnon; Jose A Plaza; Calvin B Williams; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2014-04-29       Impact factor: 8.551

8.  The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

Authors:  Ce Tiffon; Je Adams; L van der Fits; S Wen; Pa Townsend; A Ganesan; E Hodges; Mh Vermeer; G Packham
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 9.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

10.  Long-term interleukin-10 presence induces the development of a novel, monocyte-derived cell type.

Authors:  C Schoenbein; W-D Docke; K Wolk; G Belbe; C Hoflich; M Jung; G Grutz; W Sterry; H-D Volk; K Asadullah; R Sabat
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.